In the news
Biogen Pharmachem Q1 profit plunges 83.58% to ₹0.22 crore
Biogen Pharmachem posts ₹1.00 cr Q4 profit vs ₹0.36 cr loss last year
Biogen buys Apellis for $5.6B to boost rare disease portfolio
Biogen gets FDA approval for higher Spinraza dose, shares rise 3%